ImmunityBio Inc. stocks have been trading down by -10.62 percent following bearish sentiment over its clinical trial outlook.
Click Here for a Millionaire's POV on Trading IBRX
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- The FDA issued a Warning Letter saying Anktiva promotions were false or misleading, including hints it could cure or prevent all cancer, helping trigger about a 21% IBRX selloff on 2026/03/24.
- A securities-fraud class action now targets ImmunityBio and Patrick Soon‑Shiong, alleging Anktiva’s capabilities and regulatory profile were overstated to the market.
- Multiple law firms are recruiting traders who bought IBRX between 2026/01/19 and 2026/03/24, pointing to a 2026/05/26 deadline to seek lead-plaintiff status.
- IBRX also dropped more than 12% after updated Phase 2 glioblastoma data for an Anktiva regimen, reinforcing claims that expectations around the drug were unrealistic.
Live Update At 14:02:44 EDT: On Thursday, May 07, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending down by -10.62%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
ImmunityBio Inc. sits in classic high‑risk biotech territory. Revenue over the last year was about $113.3M, yet IBRX carries an enterprise value near $5.27B, meaning traders are paying roughly 70 times sales for the story. That is rich, even by biotech standards, and it leaves very little room for disappointment.
Margins underline how early‑stage this story is. ImmunityBio’s EBIT margin is around ‑278%, and profit margin is worse than ‑300%. In plain language, the company is losing several dollars for every dollar it brings in. Returns on assets are deeply negative, reflecting heavy spending on R&D and infrastructure with no sustained profit stream yet.
On the plus side, the balance sheet for IBRX shows cash and short‑term investments of about $242.8M and a strong current ratio around 5.1, so near‑term liquidity looks solid. But free cash flow was roughly ‑$71.7M in the latest quarter, showing the burn continues. That combination – big losses, strong cash, and a premium valuation – means IBRX trades more on headlines, data readouts, and regulatory news than on current fundamentals.
More Breaking News
- Datadog Stock Jumps As AI Bets Ignite Bullish Targets
- SABR Stock Draws Focus As Alaska–Hawaiian Integration Showcases Platform
- SiTime Stock Jumps After Big Earnings Beat And AI Push
- AAON Stock Jumps As Traders Brace For Earnings Call
From a price‑action standpoint, the daily chart shows IBRX grinding higher from about $7.10 on 2026/04/30 to the $7.49 close on 2026/05/07, with spikes above $8 along the way. The intraday tape today shows a fade from premarket highs near $8.45 down into the mid‑$7s, signaling selling pressure into strength and active trading around news flow.
Why Traders Are Watching IBRX Right Now
IBRX is on every momentum trader’s radar for one simple reason: regulatory shock plus class‑action headlines equals volatility. The core story starts with Anktiva, ImmunityBio’s bladder‑cancer drug and lead biologic. According to multiple reports, the FDA issued a formal Warning Letter after finding that TV and podcast promotions for Anktiva were “false or misleading.” Regulators said the materials suggested Anktiva could cure or prevent all cancers and even pushed an unapproved subcutaneous route of administration.
When that FDA Warning Letter became public on 2026/03/24, IBRX dropped about 21% in a single session, erasing close to $2B in market cap by some accounts. For short‑term traders, that was a textbook gap‑down panic. For longer‑term holders, it was a wake‑up call about regulatory‑communication risk.
The damage did not stop there. A securities‑fraud class action now alleges ImmunityBio, including CEO Patrick Soon‑Shiong, overstated what Anktiva can do and failed to fully disclose how aggressive the promotional practices were. Law firms are targeting traders who bought IBRX between 2026/01/19 and 2026/03/24, with a key 2026/05/26 deadline to seek lead‑plaintiff status. That creates a calendar of legal headlines the market will track closely.
Layered on top of the FDA issue, IBRX also sold off more than 12% after updated Phase 2 results for a glioblastoma regimen involving Anktiva. Those trial updates reinforced the argument in the lawsuits – that expectations for Anktiva’s broad cancer potential were set too high. Put together, ImmunityBio now faces regulatory, legal, and data‑perception overhangs. That mix tends to keep a stock like IBRX highly reactive to every new filing, press release, or rumor.
Conclusion
For active traders, ImmunityBio Inc. is a classic “story stock” entering a hard reality check. On one hand, Anktiva is an approved bladder‑cancer drug with massive theoretical upside if future data support broader cancer uses. On the other, IBRX is now under the microscope for how that upside was sold to the public. An FDA Warning Letter calling promotional materials misleading, plus a roughly 21% one‑day collapse and follow‑on class actions, has shifted the narrative from pure biotech optimism to serious questions about governance and disclosure.
The latest price action – sharp moves above $8 followed by intraday fades into the mid‑$7s – tells you traders are actively fading spikes and treating every bounce in IBRX as a trading vehicle, not a safe haven. While the balance sheet shows enough cash for now, the combination of heavy losses, premium valuation, and legal uncertainty raises the bar for any sustained uptrend. Headline risk is now the main driver.
For those studying this for education and research, IBRX is a live case study in how quickly sentiment can flip when regulators step in. As Tim Sykes likes to say, “The market doesn’t care about your opinion, only about price action and risk.” As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” Traders who follow ImmunityBio need to focus on both – mapping key legal dates, watching every new Anktiva data update, and, above all, cutting losses fast when the tape turns against them. This coverage is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.